Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH MOTRIN vs MOTRIN IB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
FDA-approved for relief of mild to moderate pain,fever reduction,off-label uses include migraine and dysmenorrhea
Relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscle aches, or minor pain of arthritis,Reduction of fever
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation.
Primarily hepatic via cytochrome P450 2C9 (CYP2C9) and, to a lesser extent, CYP2C8; undergoes glucuronidation.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
99% bound to albumin.
Approximately 99% bound to plasma albumin.
0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment.
Apparent volume of distribution is 0.15 L/kg (range 0.10–0.20 L/kg), consistent with low tissue penetration and high plasma protein binding.
Oral: 80-100% (rapid absorption); rectal: approximately 70-80%.
Oral: ~80% (rapidly and completely absorbed; first-pass metabolism reduces absolute bioavailability to 80% of the dose).
GFR 30-59 m L/min: reduce dose by 50% or avoid; GFR <30 m L/min: contraindicated.
GFR 30-60 m L/min: no adjustment needed; GFR 10-29 m L/min: reduce dose by 25-50%; GFR <10 m L/min: avoid use or reduce dose by 50%.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day or single doses not exceeding 400 mg.
Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours.
Initiate at the lowest effective dose, typically 200-400 mg every 6-8 hours; maximum 1200 mg/day; monitor renal function and potential for GI bleeding.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk. Additionally, NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions such as Stevens-Johnson syndrome; avoid use in late pregnancy
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
Hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; active peptic ulcer or gastrointestinal bleeding; advanced renal disease
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol while taking this medication as it increases risk of stomach bleeding.
Concomitant intake of alcohol may increase risk of gastrointestinal bleeding. No specific food restrictions; however, taking with food may reduce GI irritation. Avoid grapefruit juice? No significant interaction known.
First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation.
First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dysfunction. Third trimester: Known risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios, and necrotizing enterocolitis. Use contraindicated after 30 weeks gestation.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Amount ingested by infant <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects and renal function.
No specific dose adjustment is recommended in pregnancy for occasional use. However, due to pharmacokinetic changes (increased volume of distribution and clearance), lower doses may be less effective; use the lowest effective dose for the shortest duration. Avoid routine use after 20 weeks due to fetal risks.
Increased volume of distribution and renal clearance in pregnancy may reduce serum concentrations. However, due to fetal risks, dose adjustments are not recommended; instead, avoid use after 30 weeks and limit to lowest effective dose with shortest duration in earlier trimesters.
For pediatric patients, use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure efficacy and safety. Limit to 4 doses per day; maximum 40 mg/kg/day or 1.2 g/day, whichever is less. Do not combine with other NSAIDs. Use lowest effective dose for shortest duration. Contraindicated in children with active peptic ulcer disease, severe renal impairment, or known hypersensitivity to ibuprofen or aspirin.
Motrin IB (ibuprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, fever, and inflammation. Onset of analgesia is within 30-60 minutes. It is more effective than acetaminophen for inflammatory pain. Maximum single OTC dose is 400 mg; maximum daily OTC dose is 1200 mg. Chronic use increases risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with significant renal impairment (e GFR <30), active peptic ulcer disease, or prior hypersensitivity to NSAIDs. Use with caution in patients with hypertension, heart failure, or on anticoagulants. Ibuprofen may reduce the cardioprotective effect of low-dose aspirin if taken simultaneously; separate dosing by at least 2 hours.
Give with food or milk to reduce stomach upset.,Use weight-based dosing: shake suspension well before use; use dosing syringe or cup provided.,Do not exceed 4 doses in 24 hours; wait at least 4 hours between doses.,Do not give with other pain relievers containing ibuprofen, naproxen, or aspirin.,Stop use and consult doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Seek medical help immediately if signs of allergic reaction (rash, hives, swelling, trouble breathing) or stomach bleeding (bloody or black stools, vomit that looks like coffee grounds) occur.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg (6 tablets of 200 mg) in 24 hours.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult a doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Do not take with other NSAIDs (e.g., naproxen, aspirin) unless directed by a healthcare provider.,Seek medical attention immediately if signs of allergic reaction (rash, hives, swelling, difficulty breathing) or stomach bleeding (black/bloody stools, vomiting blood) occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH MOTRIN vs MOTRIN IB, answered by our medical review team.
JUNIOR STRENGTH MOTRIN is a NSAID Analgesic that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. MOTRIN IB is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH MOTRIN and MOTRIN IB depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH MOTRIN is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of MOTRIN IB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH MOTRIN and MOTRIN IB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH MOTRIN is classified as Category C. First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second t. MOTRIN IB is classified as Category C. First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dys. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.